SCHEMBL731117

SCHEMBL731117

[c]1cccc(-c2cc3ccccc3s2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.53
HSD17B1 P14061 1/20 0.51
HSD17B2 P37059 1/20 0.51
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
ERN1 O75460 4/20 0.43
CYP19A1 P11511 1/20 0.40
NQO1 P15559 1/20 0.40
NQO2 P16083 1/20 0.40
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
CYP2A6 P11509 4/20 0.38
ADRB2 P07550 1/20 0.38
HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL145377 0.80 APP (0.62) APPHSD17B1HSD17B2CA1CA2
SCHEMBL163523 0.79 APP (0.71) APPHSD17B1HSD17B2CA1CA2
SCHEMBL29766071 0.79 APP (0.71) APPHSD17B1HSD17B2CA1CA2
SCHEMBL9727720 0.79 APP (0.47) APPHSD17B1HSD17B2CA1CA2
Bromide SCHEMBL31564934 0.77 APP (0.69) APPHSD17B1HSD17B2CA1CA2
SCHEMBL27631114 0.77 HSD17B1 (0.77) APPHSD17B1HSD17B2CA1CA2
SCHEMBL3807869 0.77 ESR1 (0.49) APPHSD17B1HSD17B2CA1CA2
SCHEMBL21296082 0.77 ESR1 (0.53) APPHSD17B1HSD17B2CA1CA2
SCHEMBL32677328 0.77 APP (0.81) APPHSD17B1HSD17B2CA1CA2
SCHEMBL27159530 0.77 APP (0.81) APPHSD17B1HSD17B2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109311844-A Triaizine compounds, its manufacturing method and the organic electroluminescent device as constituent 东曹株式会社 2019-02-05 CN disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 APP 4645/4885HSD17B1 435/4885HSD17B2 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.